The past few years were a period of cautious experimentation with generative AI and stabilization of post-pandemic supply chains. In 2026, the industry is poised for breakthrough growth, where success is measured not only by lab results but by how effectively therapies reach patients and communicate value.

In this article, we analyze the key trends that are redefining what it means to lead in the global pharma and biotech market.

1. The expansion of cell & gene therapies (CGT)

According to a global analysis conducted by the Towards Healthcare agency in January 2026, the cell and gene therapy market size is expected to reach $33.5 billion by the end of 2026. The other highlights include:

  • Forecasts indicate the market size will reach $232 billion by 2035.

  • The most demanding segments for cell and gene therapy innovations are oncology, cardiovascular, immunology, dermatology, and neurology. This is due to the rising prevalence of chronic disorders in these fields.

  • The North American region holds a leading position in the global market, with Asia-Pacific considered the fastest-growing and most promising.

In 2026, the expansion of cell & gene therapies is defined by a move from "scientific discovery" to "commercial realism". Companies increasingly focus on scaling product delivery and clearly communicating the value to patients. As a result, several trends appear.

Shift towards “just-in-time (JIT)” delivery

The hurdle has shifted from “Will this medicine work?” to “How can it be delivered to the patient?”, focusing on logistics and integration capabilities. Just-in-time delivery refers to how easily a complex cell & gene therapy can move from the laboratory and manufacturer to the patient's bedside within the existing healthcare infrastructure.

Since CGTs cannot be stored in a standard hospital pharmacy like traditional "off-the-shelf" drugs, the industry is standardizing how patients move through the system. The new approach demonstrates the following traits:

  • Diagnosis as a trigger. Once a local hospital confirms a diagnosis, the system doesn’t wait for the medicine to arrive. Instead, it immediately starts the preparation process at a specialized development and manufacturing center tailored for that patient.

  • Manufacturing synchronization. Because these therapies often have an extremely limited shelf life, dedicated digital systems can synchronize the patient’s arrival at the hub with the completion schedule of their personalized dose.

  • "Data-first" logistics. To save time on-site, insurance details and medical histories are transmitted digitally from the hospital to the specialized center well in advance of the patient’s arrival.

By streamlining these steps, the industry ensures that advanced treatments are accessible to patients regardless of whether their local hospital has the high-tech infrastructure to produce and store them or not.

The rise of in vivo CAR-T

Now, the industry is witnessing the maturity of in vivo CAR-T therapies, representing one of the most significant technological leaps in oncology. This evolution aims to simplify treatment by modifying cells directly inside the patient's body rather than in a lab.

A standard practice (ex vivo) involves harvesting a patient's T-cells and shipping them to a lab for genetic modification to fight cancer. They are grown in large quantities and then shipped back for infusion. This process is time-consuming (often taking weeks), incredibly expensive, and carries a high risk of logistical failures. In vivo-based approach, however, means the viral vectors or lipid nanoparticles deliver the genetic "instructions" directly into the patient's bloodstream.

As a result, clinicians eliminate the need for specialized lab manufacturing and cell harvesting, which moves CAR-T from being a complex surgical-like procedure toward a more traditional infusion that can be administered in a standard clinic. As of 2026, these therapies are moving from "preclinical promise" into early clinical trials, providing the first real-world data on whether "inside-the-body" modification is as effective as lab-based methods.

Regulatory and strategic de-risking

To combat the high costs and risks associated with CGT, many pharma developers are using investigator-sponsored trials in other regions. For example, a UK drugmaker, AstraZeneca, will invest $15 billion in China through 2030. Their goal is to expand R&D capabilities, find alternative markets, and generate early human proof-of-concept data before pursuing larger-scale global trials.

2. Next-generation mRNA therapeutics

The next trend in pharma and biotech refers to mRNA therapeutics. A Nova One Advisor report of December 2025 presents the following highlights:

  • The global mRNA therapeutics market was valued at $17.25 billion in 2025 and is projected to surpass around $83.49 billion by 2035, registering a CAGR of 17.08% over the forecast period of 2026 to 2035.

  • The Asia-Pacific mRNA therapeutics market is expected to grow the fastest from 2026 to 2035.

  • The oncology segment is expected to register the highest CAGR over the forecast period.

  • The US-based companies such as Moderna, Pfizer-BioNTech, and Arcturus Therapeutics continue to lead in clinical trials, FDA approvals, and innovation ecosystems in the mRNA field.

RNA modalities diversification

As of 2026, we may see more ways to modify RNA to influence gene expression and cellular functions.

The diversification of RNA modality means that different types of RNA, such as mRNA, tRNA, rRNA, and ncRNA, can undergo biochemical modifications that affect their structure, function, and regulation. These modifications can play a significant role in gene regulation, protein synthesis, and disease progression. The ability to manipulate RNA through modifications opens up new opportunities for therapeutic applications, allowing for targeted treatments and the potential to address a wide range of diseases.

Greater focus on data-driven RNA engineering

One of the most prominent shifts is the rise of data-driven RNA engineering. As RNA modalities diversify and regulatory policies become stricter, the traditional pipelines on which scientists relied on experience and educated guessing are no longer efficient. Now, the priority is given to evidence-based decision-making grounded in high-quality biological data.

The greatest advancement in this field is sequence-based analytics. It is a new approach in RNA drug development that helps to analyze the exact molecular structure, behavior, and quality of an RNA therapy. The method allows solving three key problems:

  • Ensure structural validation. Sequencing-based analytics uses specialized digital tools that can detect exactly how an mRNA strand folds within its delivery vehicle (if not, the drug can be useless). For example, RNAComposer is a digital tool that predicts large RNA 3D structures based on machine translation and RNA databases.

  • Identify impurities. A major risk in mRNA manufacturing is the inadvertent production of double-stranded RNA (dsRNA), which can trigger a dangerous immune response in patients. Sequencing analytics can pinpoint these impurities with far greater sensitivity than standard assays, ensuring the final product is safe.

  • See direct RNA sequencing. Unlike older methods that required converting RNA into DNA first (cDNA sequencing), new technologies allow for direct RNA sequencing. This allows scientists to see chemical modifications on RNA that influence how long it lasts in the body and where and why an RNA strand breaks down over time.

The sequence-based analytics provides biological evidence for RNA drug development launches. It allows companies to compare different manufacturing batches to ensure every dose is identical, regardless of which factory produced it. The method is already used by renowned pharma and biotech companies, like EclipseBIO.

3. AI-driven drug discovery & clinical trials

The biotech market demonstrates stable growth in AI adoption. For instance, a report presented by Precedence Research in November 2025 on AI implementation in US biotech companies highlights the following statistics:

  • The AI in the biotech market size reached $2.5 billion in the first quarter of 2026.

  • By 2034, the market size is expected to reach $10.5 billion.

  • The market growth is driven by AI adoption in drug discovery, precision medicine, and genomics.

These statistics prove that in 2026, artificial intelligence will become the engine powering the entire chain of drug development. The core trend is a shift from using AI for discovery alone to embedding it deeply into the clinical development process, fundamentally changing the way drugs are tested and brought to patients.

A female pharmaceutical scientist analyzes complex AI-driven drug discovery data on dual monitors. She is focused on 3D molecular models and chemical structures

Historically, over 80% of clinical trials fail to meet enrollment timelines, and patient recruitment remains a major bottleneck. Dedicated AI platforms can be used to de-risk this process from the start. By analyzing real-world data, electronic health records, and even insurance claims, AI can predict which trial sites will enroll patients fastest and which patient populations are most likely to meet specific inclusion criteria. This approach allows sponsors to design more realistic protocols and identify pre-qualified patients before a trial even launches, significantly reducing costs and time spent on patient recruitment.

4. Omnichannel HCP engagement

In 2026, engagement among healthcare professionals and institutions has evolved from "digital-first" to "relevance-first." As medical information becomes more dense, pharma companies have pivoted toward an integrated, data-driven ecosystem that values the HCP’s time and specific clinical context. As a result, there are several highlights of the trend.

Integration across channels

The omnichannel approach means that communication channels become a synchronized web. Whether an HCP interacts with a medical science liaison in person, browses a digital portal, or attends a virtual symposium, the experience is consistent.

The key approach here is the adoption of a hybrid model. Here, digital and physical touchpoints are linked. For instance, a physical interaction at a conference booth can trigger a personalized digital follow-up containing the exact clinical data the HCP expressed interest in during the face-to-face talk.

AI-based data-driven personalization

The priority for 2026 is launching contextually relevant communication. This implies targeted messaging where content is tailored to an HCP’s specialty, past interaction history, and real-world prescribing needs. At the same time, artificial intelligence and machine learning act as helpers and orchestrators of the process, and the modern HCP engagement presents the following highlights:

  • Modular content. Now, many companies use content blocks — short, compliant snippets of video or text that an AI can assemble in real-time to match an HCP’s preferred communication style.

  • Next-best-action. Predictive models analyze millions of data points to suggest the optimal time, channel, and message for the next interaction, ensuring that outreach feels like a helpful service rather than an interruption.

  • Sentiment analysis. ML tools process feedback from various channels to adjust the communication tone, ensuring it resonates with the current clinical challenges faced by providers in specific regions.

5. Visualizing complexity with 3D mechanism of action animation

The industry witnesses an increased need for engaging scientific storytelling. As therapeutic modalities like ADCs, radiopharmaceuticals, and gene editors become increasingly complex, 3D medical animation has become an essential precision tool for the industry.

Statistics provided by Precedence Research highlight the following facts:

  • The global medical animation market had already surpassed $600 million by the beginning of 2026. In 10 years, the number is predicted to increase fivefold.

  • By therapeutic area, oncology and cardiology segments generate the largest revenue share and are expected to expand fastest.

  • By application, the drug’s MoA accounted for around 45% of the market revenue share.

The same report announces several factors that drive the market growth and adoption of medical animations:

  • The expanding biopharmaceutical sector relies on medical animation for visualizing drug mechanisms, molecular processes, and disease pathways.

  • The need for compliant and accurate medical illustrations to meet regulatory standards drives the demand for high-quality medical animation in the healthcare and pharmaceutical industries.

  • Healthcare providers and pharmaceutical companies leverage medical animation as a strategic tool in marketing campaigns to effectively communicate product benefits and mechanisms of action.

A female scientist in a lab coat points to a large screen displaying microscopic cellular structures at a biotech conference. She is explaining her findings to two professionals

In other words, the dominance of the MoA videos in the entire medical animations market proves that pharma and biotech stakeholders seek visual fidelity to drive three critical outcomes:

  • Clinical clarity. By simplifying complex oncology and cardiology treatments, animations ensure that HCPs and investors make informed prescribing decisions faster.

  • Regulatory trust. High-quality 3D visualizations reduce the friction in drug approvals by providing regulators with a transparent, step-by-step look at molecular interactions.

  • Commercial differentiation. In a crowded biopharma market, the ability to tell an engaging, scientifically accurate visual story is what can change an audience's opinion of an innovative therapy your company promotes.

Curious what your animation might cost?

Get a ballpark estimate now!

Check cost

6. The spread of advanced CDMO partnerships & continuous manufacturing

2026 also demonstrates remarkable developments in partnership policies with contract development and manufacturing organizations. The report provided by Research and Markets in February 2026 forecasts that by the end of the year, the global CDMO market size will reach $275 billion, implying an annual growth rate of 6.5% compared to 2025.

The report also indicates several factors that define both the market growth and the evolution of CDMO partnerships.

First, we may observe the increasing outsourcing volume by large companies. As R&D costs increase, large biotech and pharma companies try to “delegate” non-core manufacturing. Through that, they free resources for research and discovery needs while maintaining the uninterrupted operation of the global supply chain.

Second, the CDMO-oriented approach is advantageous for emerging markets. For small local companies, building and maintaining massive biological labs or large manufacturing centers is extremely expensive. By partnering with advanced CDMOs, these companies gain immediate access to required technologies and platforms (such as mRNA or cell-free DNA manufacturing facilities) without the massive upfront investment.

Finally, one of the key trends in this field is consolidation toward end-to-end one-step CDMO. It means that now pharma and biotech companies tend to shift from a “fragmented” model to a “unified” one. Previously, in pharma outsourcing, a standard practice was to find different vendors for different operations (one for discovery, a second for clinical trials, and so on). Now, everyone is trying to find an outsourcing partner that will take responsibility for the whole development cycle.

Such a policy provides faster market delivery for new drugs and reduced manufacturing costs. Furthermore, an end-to-end CDMO model implies consistency in the development, as no “misreading” of research data and additional manufacturing flaws are expected.

7. Supply chain reshoring and biopharma M&A

As of 2026, the biopharma industry is going through a structural realignment driven by geopolitical tensions and the need for operational anti-fragility. This has resulted in a shift from hyper-globalized, lean supply chains toward localized resilience and strategic consolidation.

Following the supply chain shocks of previous years, 2026 sees a massive investment in domestic manufacturing capabilities, particularly in the US and EU. Governments are providing heavy subsidies for "reshoring" the production of Active Pharmaceutical Ingredients (APIs) and essential medicines to reduce dependence on distant or politically unstable regions.

In addition, companies are adopting new inventory models. This includes building "mirrored" manufacturing sites, where a facility in the West is an exact technological replica of one in Asia, ensuring that production can be shifted instantly if one region faces a disruption.

Finally, M&A is also being used for de-risk policy by entering high-growth emerging markets through local partnerships. Similar to AstraZeneca’s $15 billion investment in China, North American and European companies are using M&A to buy local expertise and clinical trial infrastructure. This allows them to generate "Human Proof of Concept" data in diverse populations more quickly and cost-effectively than in traditional Western markets.

Conclusion

The trends observed in 2026 signal that success in this high-stakes environment now requires a seamless fusion of innovative science and high-fidelity presentation. Whether through "one-stop" CDMO partnerships or 3D animations that translate molecular complexity into clinical clarity, the industry is prioritizing transparency.

Companies that can synchronize their data, localize their supply chains, and engage healthcare providers with personalized, context-aware narratives will dominate the market.

If you want to effectively communicate your discoveries and developments to the public, visualize the most complex mechanisms of drug action, and transform raw scientific data into engaging visual strategies, turn to VOKA. We create high-quality 3D animations and interactive solutions that help ensure your brand’s leadership in the industry of 2026.

FAQ

1. What are the biggest biotechnology industry trends in 2026?

In 2026, the industry is defined by focusing on the reliable delivery of complex therapies. Key shifts include the maturity of cell and gene therapies, the rise of "one-stop" CDMO partnerships, and a strategic move toward supply chain reshoring to ensure global operational stability in times of geopolitical instability.

2. How is artificial intelligence changing drug discovery?

AI implementation allows the creation of a comprehensive R&D operating system. It accelerates timelines by reducing preclinical development to under 18 months, identifies high-potential genomic targets with greater accuracy, and uses predictive simulations to detect safety issues early, significantly lowering the failure rates of expensive late-stage clinical trials.

3. Why do biotech companies need 3D MoA animation for fundraising?

As modalities such as ADCs and gene editors become more complex, 3D animations bridge the "clarity gap" for investors. These visual tools translate abstract molecular interactions into tangible proof-of-concept narrations, helping startups differentiate their innovations and secure capital by providing a deep explanation of their nature and clinical impact.

4. Why is supply chain reshoring important for biopharma in 2026?

Reshoring builds an anti-fragility basis against global disruptions. By bringing the production of active ingredients and essential medicines back to domestic or "friendly" regions, companies reduce dependency on unstable trade routes. This localized approach ensures a consistent medicine supply and maintains higher regulatory oversight of manufacturing quality.